Last reviewed · How we verify
A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy in Treatment Naive Children With Growth Failure Due to Insufficient Secretion of Endogenous Growth Hormone (BPLG-004)
The purpose of this study is to compare a new weekly administered growth hormone preparation with standard daily treatment in children with insufficient secretion of growth hormone
Details
| Lead sponsor | LG Life Sciences |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 144 |
| Start date | 2005-09 |
Conditions
- Growth Hormone Deficiency (GHD)
Interventions
- growth hormone (somatropin)
Primary outcomes
- Height velocity at the end of 12 months treatment — 12 months
Countries
United States